MERCK & CO., INC. (MRK)
Clinical trial NCT06016920 updates: 1. completion date: 2028-01-01 → 2030-12-01 2. primary completion date: 2027-09-01 → 2029-01-01 3. enrollment: 51 → 110 participants 4. allocation: NON_RANDOMIZED → RANDOMIZED 5. intervention model: SEQUENTIAL → PARALLEL
📉 **NEGATIVE** • Medium confidence analysis (69%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (20%) **Content type:** Clinical